Erytech’s lead indication, acute lymphocytic leukaemia (ALL), is being explored in a comprehensive programme for its Graspa technology, with acute myeloid leukemia (AML) and pancreatic cancer following next. Key clinical data are expected for all three indications during the next 12 months, with the hallmark event being expected approval of the marketing application for Graspa for relapsed/refractory ALL in Europe by end-2016/early 2017. Our valuation of Erytech remains largely unchange
29 Jul 2016
Dense newsflow during next 12 months
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Dense newsflow during next 12 months
PHAXIAM Therapeutics S.A. (PHXM:PAR) | 0 0 0.0%
- Published:
29 Jul 2016 -
Author:
Dr Jonas Peciulis -
Pages:
8
Erytech’s lead indication, acute lymphocytic leukaemia (ALL), is being explored in a comprehensive programme for its Graspa technology, with acute myeloid leukemia (AML) and pancreatic cancer following next. Key clinical data are expected for all three indications during the next 12 months, with the hallmark event being expected approval of the marketing application for Graspa for relapsed/refractory ALL in Europe by end-2016/early 2017. Our valuation of Erytech remains largely unchange